How to Identify High-Quality Research Peptides – A Guide to Analytical and Purchasing Standards

The following article is educational in nature and provides an overview of analytical standards used in research peptidology and the regulatory status of peptides as laboratory reagents in the European Union. The text does not constitute legal or medical advice. Peptides from the One Peptides catalog are intended for Research Use Only – they are not drugs, dietary supplements or products intended for human consumption.
In 2017, Van Wagoner et al. published a study in JAMA comparing the purity of 44 products sold as SARMs and peptides purchased from online suppliers. The results were instructive: only 41% of the products contained the declared substance in the declared amount, approximately 9% of the products did not contain any active substance and 25% contained substances not disclosed on the label. Alternative compounds (e.g. ibutamoren or GW-501516) were detected in 39% of the products instead of the declared substance (Van Wagoner et al., 2017).
This work is the most frequently cited warning in the research peptidology literature: the certificate provided by the supplier does not always correspond to reality. A standard is only as good as the quality system of the company issuing it. For research teams, authors of publications and people using peptides in laboratory experiments, the ability to assess the quality of a peptide is the first element of any research toolkit – without it, all subsequent work is built on sand.
This article collects quality standards used in research peptidology: how to read an HPLC chromatogram, what to require from a certificate of analysis, how to recognize a questionable supplier and what legal status peptides have as laboratory reagents in Europe.

Contents

1. What does “research grade” mean in the context of research peptides
2. HPLC – the foundation for assessing peptide purity
3. Mass spectrometry – verification of molecule identity
4. Full QC package – Karl Fischer, endotoxins, sterility
5. Certificate of Analysis (COA) – what it must contain
6. Red flags – how to recognize a questionable supplier
7. Legal status of research peptides in Europe
8. FAQ
9. Bibliography

1. What does “research grade” mean in the context of research peptides

The term “research grade” (RUO – Research Use Only) defines a category of reagents intended exclusively for laboratory and research applications. This status differs fundamentally from three other categories of peptide products:

Category	Quality standards	Registration routes	Anwendung
Pharmaceutical grade (GMP)	Full Good Manufacturing Practice system, validation of every stage of production	EMA/FDA, registration dossier	Medicines for people
Reagent grade / Research grade (RUO)	HPLC ≥98%, MS, basic analytical package	No therapeutic registration	Laboratory, in vitro, in vivo tests on animals
Cosmetic grade	Cosmetic standards (varies by jurisdiction)	Cosmetic notification	Cosmetics ingredient
Food grade / Supplement grade	Food standards, EFSA	Notification as food or supplement	Human consumption

1.1 RUO is not worse – it is different

A common misunderstanding is to treat “research grade” as a lower category than “pharmaceutical grade”. This is a simplification. An RUO peptide with HPLC purity of 99.5% can be chemically identical to its pharmaceutical counterpart – the difference lies not in the molecule, but in the production process documentation system.
GMP requires validation of each stage (premises, equipment, personnel, raw materials, batch documentation) in accordance with pharmaceutical standards. RUO requires documentation of the quality of the final product (HPLC chromatogram, MS spectrum, purity report) without the need to validate the entire production ecosystem.
For scientific research, in vitro experiments, animal models and laboratory applications, RUO is the industry standard and sufficient. For human therapy, RUO is insufficient and not legally allowed – a full drug registration pathway is required.

1.2 Implications for the RUO user

RUO status has three consequences:

• No Therapeutic Claims – An RUO supplier cannot (and should not) advertise a peptide as a “drug”, “therapy”, or use language that suggests health effects
• No registration as a product for consumption – RUO peptides are not dietary supplements in the Polish or European legal sense
• Full responsibility on the part of the buyer for the method of use – the peptide is intended for research, the method of conducting it is the responsibility of the laboratory

2. HPLC – the foundation for assessing peptide purity

High-Performance Liquid Chromatography (HPLC) is the standard for determining purity in research peptidology. Reverse phase separation (RP-HPLC) allows you to separate the target peptide from structurally related impurities: peptides with missing amino acids (deletion peptides), peptides with added amino acids, stereoisomers, hydrolytic fragments.

2.1 How reverse phase separation works

In RP-HPLC, the chromatographic column is filled with a hydrophobic sorbent (usually C18 – silica gel modified with 18-carbon hydrocarbon chains). The mobile phase is an aqueous mixture with organic modifiers (acetonitrile, methanol) and an ion-pairing agent (usually TFA – trifluoroacetic acid).
The peptide passes through the column at a speed depending on its hydrophobicity – more hydrophobic molecules (with more aromatic residues or aliphatic chains) are retained longer. The UV detector (usually at a wavelength of 214 nm – absorption of peptide bonds; in the operating range of 210-220 nm) records the flow of individual fractions in the form of a chromatogram.

2.2 How to read an HPLC chromatogram

A typical chromatogram of a research peptide shows:

• Main peak – Corresponding to the target molecule, usually the largest
• Co-peaks – Minor impurities, usually close to the main peak
• Baseline – detector signal without analyte

Peptide purity is calculated as the ratio of the area under the main peak to the sum of the areas under all peaks in the chromatogram. The result is expressed as a percentage. The industry standard in research peptidology is ≥98%.
Sample chromatogram of BPC-157 (purity 98.7%)
Signal │
       │            ┃
       │            ┃
       │            ┃
       │            ┃
       │            ┃
       │     │      ┃        │
       │__|__│______┃________│___
                main
                peak

2.3 What distinguishes a good chromatogram from a poor one

Features of a high-quality peptide chromatogram:

• Sharp, symmetric main peak – A broad, asymmetric peak indicates heterogeneity or problems with the column
• Low, stable baseline – Noise or a drifting baseline reduces integration precision
• Small and few accompanying peaks – many small peaks (>1% of the area) indicate the presence of synthesis by-products
• Retention time consistent with standard – A retention time deviation from standard suggests problems with the identity of the molecule

A “98% pure” peptide in an unreadable chromatogram with a drifting baseline may actually be a 90% peptide whose area under the main peak has been poorly integrated. Purity should always be verified on a chromatogram, not just on a declaration.

2.4 What HPLC means – and what it doesn’t mean

HPLC measures relative purity – what percentage of the recorded signal is the target peptide. It does not answer the questions:

• Is the recorded peak actually a peptide with the declared sequence? — this is verified by mass spectrometry (section 3)
• How much peptide is in the vial? — this is verified by peptide content determination, usually by amino acid or UV analysis
• Is the peptide free of endotoxins and microorganisms? — this is verified by microbiological tests (section 4)

Therefore, “HPLC ≥98%” is the first quality assessment element, but not the only one. The full analytical suite includes several parallel techniques.
A complete guide to analytical methods in peptidology can be found in the dedicated article HPLC vs MS – methods for analyzing peptide purity.

3. Mass spectrometry – verification of molecule identity

Mass Spectrometry (MS) answers the question that HPLC cannot answer: whether the molecule we have in the vial is what we say it is. The mechanism of the technique involves ionization of the peptide, separation of ions according to the mass to charge ratio (m/z) and detection.

3.1 Ionization techniques in peptidology

In laboratory practice, peptides are most often analyzed using two methods:

• ESI-MS (Electrospray Ionization) — the peptide in the solution is sprayed by an electrostatically charged needle; multiply charged ions [M+nH] are formed. Fast technique, easily combined with HPLC in LC-MS systems.
• MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization – Time of Flight) – a peptide in a mixture with a matrix (e.g. CHCA – α-cyano-4-hydroxycinnamic acid) ionized by a short laser pulse. It produces mainly singly charged ions [M+H]⁺.

Both techniques produce a mass spectrum – the dependence of signal intensity on m/z. The appearance of a peak at m/z corresponding to the theoretical monoisotopic mass of the peptide confirms the identity.

3.2 What the mass spectrum verifies

The full MS report confirms:

• Molecular mass consistent with the theoretical – accuracy <10 ppm (less than 0.001%) in modern high-resolution spectrometers (Orbitrap, Q-TOF)
• Isotope distribution consistent with theory – a peptide is a molecule with a complex isotopic profile (¹²C/¹³C, ¹H/²H) that must match the expected profile
• No major contaminants of detectable mass – e.g. peptides with missing amino acid residues (deletions)

In advanced analysis (MS/MS, peptide fragmentation into characteristic ions), the full amino acid sequence can be verified, not only the molecular mass. The standard for research peptides is ESI-MS with monoisotopic mass verification; MS/MS is used when in doubt or in peptides with unusual modifications.

3.3 HPLC + MS – why together

HPLC says: “98% of the signal is the same molecule.” MS says: “this molecule has a mass consistent with the declared sequence.” Together they provide a qualitative picture: the peptide is both pure and correctly identified.
One of the techniques without the other leaves gaps in interpretation. HPLC alone does not protect against a situation in which the supplier provided a different peptide – pure in the declaration, but in fact a different sequence. MS alone does not protect against a peptide of the correct mass but heavily contaminated with fragments of the same nominal mass. A complete COA must include both elements.

4. Full QC package – Karl Fischer, endotoxins, sterility

Chromatographic purity and mass identity are the two cornerstones of peptide evaluation. For research applications in living models (especially animal models), additional elements are needed.

4.1 Karl Fischer – residual moisture in the lyophilisate

Most research peptides are delivered in the form of lyophilisate (dried after freezing). The residual moisture of the lyophilisate affects three aspects:

• Long-term stability – the peptide is susceptible to hydrolysis in a humid environment
• Dosage Accuracy – High water content distorts calculations of the mass of peptide in the vial
• Microbiology – wet freeze-dried products are susceptible to the growth of microorganisms

Industry standard: ≤5% water content measured by the Karl Fischer method. Hygroscopic peptides (especially those containing asparagine, glutamine, arginine) require special control.

4.2 Endotoxin test – important for animal models

Endotoxins (lipopolysaccharides, LPS) are fragments of the membrane of Gram-negative bacteria. Their presence in the peptide applied in vivo causes a strong inflammatory response that distorts the experimental results – it modifies cytokines, activates TLR4, and induces fever.
The standard testing method is the LAL (Limulus Amebocyte Lysate) test. Industry Standards:

Anwendung	Maximum endotoxin levels
In vitro (cell cultures)	≤1 EU/mg
Animal models	≤0.5 EU/mg (preferred)
LPS-sensitive cultures	<0.1 EU/mg

EU = Endotoxin Unit – a unit of endotoxin activity, measured in the LAL test.

4.3 Sterility test

A sterility test (in accordance with the pharmacopoeia – USP <71> or Ph. Eur. 2.6.1) confirms the absence of live microorganisms in the product. The peptide in a contaminated vial after reconstitution and incubation at 37°C may develop a bacterial flora that interferes with the experiments.
For RUO peptides, a sterility test is not always standard. However, it is important for peptides used in in vivo injection models.

4.4 Full package as standard

A professional supplier of research peptides should provide for each batch:

• HPLC – chromatogram with declaration of purity
• MS – spectrum with molecular mass declaration
• Karl Fischer – Water Content Report
• LAL – endotoxin report (at least for injectable peptides)
• Amino acid analysis of peptide content – optional, for peptide content declaration

Full insight into the quality control procedure and sample analytical documents can be found on the quality testing and certificates page.

5. Certificate of Analysis (COA) – what it must contain

The Certificate of Analysis (COA) is a document summarizing the quality control results of a batch of peptide. A professional COA should include the following elements:

5.1 Lot identification

• Peptide name – complete, unambiguous nomenclature (amino acid sequence, common name, possible CAS or UNII identifiers)
• Batch/lot number – a unique identifier that allows the COA to be associated with the vial
• Date of synthesis/date of COA issuance
• Shelf life – Typically 18-24 months for lyophilized product under storage conditions

5.2 Theoretical specification

• Amino acid sequence – in one-letter or three-letter code
• Theoretical molecular mass – calculated from the sequence
• Molecular formula
• Physical state – usually “white lyophilized powder”

5.3 Analysis results

• HPLC purity – with chromatogram included
• MS Identity – with spectrum (or report) attached
• Water content (Karl Fischer)
• Endotoxins (LAL) – for injectable peptides
• Sterility – optional
• Peptide content – percentage of peptide in the lyophilized product (takes into account residual water, salts, counter-ions)

5.4 Signatures and recording of conditions

• QC employee’s name/qualifications
• Storage conditions
• RUO note – clearly marked “For Research Use Only. Not for human use.”

6. Red flags – how to recognize a questionable supplier

The market for research peptide suppliers is very diverse in terms of reliability. The following list collects signs that should raise caution.

6.1 Therapeutic Claims and Health Suggestions

RUO status precludes therapeutic claims. A supplier who writes on the product page:

• “Cures [the disease]”
• “Effective in the treatment of [condition]”
• “Recommended dosage for humans: X mg per day”
• “Safe for long-term human use”

— crosses the line of RUO status and signals a lack of understanding (or conscious disregard) of the regulatory framework. A professional RUO peptide supplier describes the peptide through the lens of scientific literature and molecular mechanisms, not through health promises.

6.2 No COA or Generic COA

Warning Signals:

• There is no certificate of analysis for the purchased batch
• A “template” COA that looks the same for all batches and contains the same values
• COA without a chromatogram, only with a declaration of purity
• The lot number on the vial does not match the COA
• COA without peptide sequence, molecular weight or other technical elements

6.3 Surprisingly low prices

The synthesis of a research peptide with HPLC purity ≥98%, with a full QC package, has its fixed costs – mainly SPPS synthesis, chromatographic purification, analytical verification. A price 10x lower than industry standards is usually a signal that a step has been omitted or the quality does not meet the declaration.

6.4 Inconsistent messages and lack of feedback

• A website full of grammatical errors or randomly copied descriptions
• No answers to technical questions about purity, sequence, batch
• Evasive answers about the origin of the peptide or the stage of synthesis
• Price changes without explanation, lack of supply chain transparency

7. Legal status of research peptides in Europe

The regulatory status of peptides in the European Union is often misunderstood. The common narrative “peptides are in a gray area” is a simplification – research peptides have a clearly defined legal status, which, however, differs from that of drugs, dietary supplements and cosmetics.

7.1 Three regulatory pathways for peptides

A peptide as a chemical molecule can fall into three separate legal categories:
Category 1 – Medicine

A peptide registered by EMA or a national registration authority (via the central or national pathway) is a medicine. Use requires a prescription, medical documentation, and clinical supervision. Examples: insulin, semaglutide (Ozempic, Wegovy), liraglutide (Saxenda).
Category 2 – Cosmetic ingredient

A peptide registered by a cosmetics manufacturer (in accordance with Regulation 1223/2009/EC) is a cosmetic ingredient. Topical application, no medical claims. Examples: GHK-Cu in anti-aging creams.
Category 3 – Laboratory reagent (RUO)

Peptide synthesized for research use, not registered as a medicine, cosmetic or supplement. Status: research chemical. Most peptides in RUO supplier catalogs are in this category.

7.2 What does the RUO status mean in European practice

RUO Peptide:

• It can be sold legally – as a chemical reagent for laboratory tests
• It cannot be advertised as a medicine or as a dietary supplement – this would be a violation of pharmaceutical or food law
• Cannot be labeled “for human consumption” – RUO label requirement: “For research use only. Not for human use”
• It does not require registration as a pharmaceutical product – because it is not sold as a medicine
• Subject to REACH registration – if sales exceed 1 tonne/year in the EU (most research peptides do not reach this scale)

7.3 What RUO Peptide is NOT

RUO peptides should be clearly separated from four other categories:

• They are not dietary supplements in the Polish or European legal sense (Regulation 178/2002/EC and Directive 2002/46/EC define a dietary supplement as a product for consumption, RUO peptide is not for consumption)
• They are not medicines – no EMA or national registration
• They are not cosmetics – unless the specific peptide has a separate cosmetic registration
• They are not controlled substances – the peptides discussed in this guide are not on the lists of the UN Convention on Narcotic Drugs (1961), the Convention on Psychotropic Substances (1971), or in the Polish registers of psychoactive substances (Journal of Laws 2024, item 1139, as amended).

7.4 RUO limit and user liability

The regulatory status of the RUO peptide defines how the peptide can be sold. It does not define how it is actually used by the end buyer. This is where the area of individual responsibility comes in:

• Peptide purchased as RUO and used in accordance with the declaration (laboratory tests, in vitro experiments, animal models in accordance with local regulations on research ethics) – completely legal situation
• A peptide purchased as RUO and used contrary to the declaration and in a manner contrary to the intended use of the product – exceeds the scope of the supplier’s offer. Liability for such use rests solely with the person who did so, not with the RUO-compliant supplier

7.5 Status of SARMs – separate track

SARMs (selective androgen receptor modulators) such as ostarine and ligandrol, and compounds often sold alongside them that are not SARMs — cardarine (a PPARδ agonist) and MK-677 (a ghrelin receptor agonist) — have partially separate status:

• WADA (World Anti-Doping Agency) places SARMs on the list of prohibited substances in professional sports (category S1.2 – other anabolic agents); cardarine is listed in section S4.4 (metabolic modulators) and MK-677 in section S2 (growth hormone secretagogues)
• In the European Union, SARMs are not registered as medicines or dietary supplements
• In chemical trade terms, SARMs are classified as laboratory reagents (RUO)

A full overview of the legal status of peptides and SARMs in Europe with reference to specific regulations can be found in the dedicated article Peptides and the law in the European Union – legal status of research reagents.

FAQ

Bibliography

1. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D (2017). Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 318(20):2004-2010. PMID: 29183075
2. Fosgerau K, Hoffmann T (2015). Peptide therapeutics: current status and future directions. DrugDiscov Today 20(1):122-128. PMID: 25450771
3. Lau JL, Dunn MK (2018). Therapeutic peptides: Historical perspectives, current development trends, and future directions
4. Hancock, W. S., Sparrow, J. T. (1981). Use of mixed-mode, high-performance liquid chromatography for the separation of peptide and protein mixtures
5. Kicman, A. T. (2008). Pharmacology of anabolic steroids
6. Thevis M, Schänzer W (2007). Mass spectrometry in sports drug testing: Structure characterization and analytical assays. Mass Spectrom Rev 26(1):79-107.
7. Aebersold R, Mann M (2003). Mass spectrometry-based proteomics
8. World Anti-Doping Agency (2024). The 2024 prohibited list — international standard
9. Andersson L, Blomberg L, Flegel M, et al. (2000). Large-scale synthesis of peptides

More articles from this cluster: all peptide quality articles.